B lymphocyte depletion with the monoclonal antibody rituximab in Graves' disease: a controlled pilot study
Research output: Contribution to journal › Journal article › Research
Graves' disease (GD) is a common TSH receptor autoantibody (TRAb)-mediated disorder. Because B lymphocytes are important self-antigen presenting cells and precursors for antibody-secreting plasma cells, temporary B-lymphocyte depletion with the monoclonal antibody rituximab (RTX) might be of benefit in GD.
| Original language | English |
|---|---|
| Journal | Journal of Clinical Endocrinology and Metabolism |
| Volume | 92 |
| Issue number | 5 |
| Pages (from-to) | 1769-72 |
| Number of pages | 4 |
| ISSN | 0021-972X |
| DOIs | |
| Publication status | Published - 1 May 2007 |
ID: 34072611